Synapse - Michael Mauro

Results (276)

Treatment free remission after combination therapy with asciminib (ABL001) plus imatinib in chronic phase chronic myeloid leukemia (CP-CML) patients who relapsed after a prior attempt at TKI discontinuation-H Jean Khoury Cure CML Consortium study

Meeting Abstract

Mauro, M.; Visotcky, A.; Flynn, K. E.; Radich, J. P.; Yang, J.; Oehler, V. G.; Cortes, J. E.; Kota, V. K.; Tantravahi, S. K.; Baim, A.; more...
Blood (2022)

Fulltext@MSK | Save

First-in-human study of Elvn-001, a highly selective BCR::ABL1 tyrosine kinase inhibitor, in patients with chronic myeloid leukemia who failed previous tyrosine kinase inhibitor therapies

Meeting Abstract

Hughes, T.; Mauro, M.; Branford, S.; Deng, W.; Wang, Q.; Collins, H.; Hochhaus, A.
Blood (2022)

Fulltext@MSK | Save

ASC2ESCALATE: A phase 2, single-arm, dose-escalation study of asciminib monotherapy in patients (Pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with 1 prior tyrosine kinase inhibitor (TKI)

Meeting Abstract

Sasaki, K.; Mauro, M.; Levy, M. Y.; Atallah, E. L.; Koller, P. B.; Maegawa, R.; Damon, A.; Kumar, J.; Khan, M.; Cortes, J. E.
Blood (2022)

Fulltext@MSK | Save

Phase I study of ruxolitinib in combination with abemaciclib for patients with primary or post-polycythemia vera/ essential thrombocythemia myelofibrosis

Meeting Abstract

Bewersdorf, J. P.; Verstovsek, S.; Derkach, A.; Masarova, L.; Pemmaraju, N.; Stein, E.; Mauro, M.; Rampal, R. K.; Bose, P.
Blood (2022)

Fulltext@MSK | Save

Dynamics of response and response factors in patients (Pts) with chronic myeloid leukemia in chronic phase (CML-CP) after ≥2 prior tyrosine kinase inhibitors (TKIs) in the phase 3 Ascembl study

Meeting Abstract

Hughes, T.; Rea, D.; Boquimpani, C.; Minami, Y.; Mauro, M.; Cortes, J. E.; Apperley, J. F.; García Gutiérrez, V.; Kapoor, S.; Allepuz, A.; more...
Blood (2022)

Fulltext@MSK | Save

Asciminib as initial therapy for patients with chronic myeloid leukemia in chronic phase (CML-CP)-H. Jean Khoury Cure CML Consortium study

Meeting Abstract

Atallah, E. L.; Visotcky, A.; Flynn, K. E.; Zhang, M. J.; Radich, J. P.; Yang, J.; Oehler, V. G.; Tantravahi, S. K.; Smith, B. D. D.; Ibarz, J. P.; more...
Blood (2022)

Fulltext@MSK | Save

Long-term molecular testing and clinical response of tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase: 5-year follow-up from SIMPLICITY, a prospective, observational study

Meeting Abstract

Cortes, J. E.; Goldberg, S. L.; Paquette, R.; Williams, L. A.; Hehlmann, R.; Michallet, M.; Gambacorti-Passerini, C.; Tang, D. R.; DeGutis, I. S.; McBride, A.; more...
Blood (2022)

Fulltext@MSK | Save

Three-year update from the optic trial: A dose-optimization study of 3 starting doses of ponatinib

Meeting Abstract

Cortes, J. E.; Deininger, M. W.; Lomaia, E.; Moiraghi, B.; Sutton, M. U.; Pavlovsky, C.; Chuah, C.; Sacha, T.; Lipton, J. H.; McCloskey, J.; more...
Blood (2022)

Fulltext@MSK | Save

Efficacy and safety of vodobatinib in patients (pts) with chronic phase Philadelphia positive chronic myeloid leukemia (Ph + CML): A sub group analysis by lines of tyrosine kinase inhibitor (TKI) therapy

Meeting Abstract

Cortes, J. E.; Saikia, T.; Kim, D. W.; Alvarado, Y.; Nicolini, F. E.; Rathnam, K.; Khattry, N.; Punatar, S.; Apperley, J. F.; Charbonnier, A.; more...
Blood (2022)

Fulltext@MSK | Save

96-Wochen update aus der phase 3 ASCEMBL studie zur untersuchung von sicherheit und wirksamkeit von asciminib vs. bosutinib bei patienten mit chronischer myeloischer leukämie in chronischer phase nach vorbehandlung mit 2 TKI

Meeting Abstract

Hochhaus, A.; Réa, D.; Saussele, S.; Buske, S.; Balabanov, S.; Lang, F.; Sauer, T.; Gattermann, N.; Mauro, M.; Minami, Y.; more...
Oncology Research and Treatment (2022)

Fulltext@MSK | Save

Michael John Mauro

Results (276)

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract

Meeting Abstract